Erik Manting's most recent trade in TransCode Therapeutics Inc was a trade of 70,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 14, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TransCode Therapeutics Inc | Erik Manting | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| TransCode Therapeutics Inc | Erik Manting | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 9,500 | 9,500 | - | - | Stock Option (Right to Buy) | |
| TransCode Therapeutics Inc | Erik Manting | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 9,500 | 9,500 | - | - | Stock Option (Right to Buy) |